This review addresses the prospect of cell therapy and GT for hereditary anemia by discussing SCD, thalassemia, FA, and G6PD deficiencies in terms of their genetic aberration, epidemiology, pathogenesis, clinical features, available management approaches and their limitations, and cell and GTs in animal models and clinical trials. The gene discussed is G6PD; the disease is hereditary anemia.